Navigation Links
Apricoxib Prolongs Time-to-Progression and Overall Survival in Biomarker-Selected NSCLC Patients
Date:6/6/2011

udy in inflammation-related pain has been completed in the United States. Superiority to placebo and an active comparator was demonstrated; safety was comparable to the active comparator.

About Tragara

Tragara Pharmaceuticals, Inc. is a privately held pharmaceutical company based in San Diego, CA. The company is focused on the clinical and commercial development of proprietary medicines for the treatment of cancer and inflammation. Tragara's lead therapeutic program, Capoxigem® (apricoxib, TG01), is currently in Phase II clinical development in lung and pancreatic cancers and has completed a Phase IIa study in inflammation/pain. A second therapeutic program, TG02, is an oral multi-kinase inhibitor that targets the major signaling pathways involving ERK5, JAK2, FLT3 and several important cyclin-dependent kinases (CDKs). TG02 is currently in phase I clinical development. The Company is also developing a "theranostic" product: ProGEM™, a proprietary diagnostic kit for the biomarker being evaluated in the Capoxigem clinical trials. Tragara is managed by a team of entrepreneurs with both Big Pharma and Biotech experience in the development and commercialization of oncology therapeutics. Its investors include: Domain Associates, Mitsubishi International Corporation, Morganthaler Ventures, Oxford BioScience Partners and ProQuest Investments.

Tragara strives to provide much-needed therapies that will contribute to patient health through better survival and an increase in the quality of life. For more information, visit www.tragarapharma.com.


'/>"/>
SOURCE Tragara Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tragara Pharmaceuticals Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis
2. Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
3. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
4. Treating Depression Prolongs Life for Older People with Diabetes
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Bayers Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
7. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
8. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
9. Dendreon Announces Exercise and Closing of Overallotment Option
10. Pharmasset Announces Exercise of Underwriters Overallotment Option
11. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 Roughly three-quarters of ... confident substituting an interchangeable biosimilar for its branded ... same nonproprietary name, according to a survey published ... Journal of Managed Care & Specialty Pharmacy ... percent of pharmacists would feel as confident if ...
(Date:2/27/2015)... Feb. 27, 2015 The role of the ... but one thing hasn,t changed: face-to-face meetings are seen ... with Key Opinion Leaders. Yet at the ... valuable type of interaction, field medical teams within the ... interactions. This is just one of the challenges addressed ...
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015  Pomerantz ... Vitae Pharmaceuticals, Inc. ("Vitae" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com ... whether Vitae and certain of its officers and/or directors ... Exchange Act of 1934.  On February ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2
... and LYNBROOK, N.Y., Aug. 31, 2011 Auxilium Pharmaceuticals, ... company, and BioSpecifics Technologies Corp. (NASDAQ: BSTC ... dismissed all pending litigation between the Companies and announced ... cellulite and human and canine lipoma as well as ...
... 31, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... Torley, M.B. Ch. B., M.R.C.P.,  as Executive Vice President ... will report to N. Anthony Coles, M.D., President and ... commercial activities related to Nexavar and the potential launch ...
Cached Medicine Technology:Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 2Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 4Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 5Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 6Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 7Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 8Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 2Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 3
(Date:2/28/2015)... “Solutionman” Haman surveyed over 10,000 people to discover what ... “The #1 block was lack of time and the ... created the Thinkubator Innovation Studio in Chicago. Statistics ... not have enough time for innovative thinking and 41% ... Solutionman’s monthly “Accelerating Innovation Training” workshops address the “lack ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... is offering a new special. Throughout all of ... , This service can help ... problems and pain. Patients may notice certain symptoms that ... relining. These symptoms include: , 1.    Pain, clicking, and ...
(Date:2/28/2015)... 28, 2015 Vancouver personal injury lawyers at ... are affected by time limits. They stated that in many ... claim or even nullify it. Many a time, delays in ... client’s rights under BC law. As a result, experts at ... accidents should consult a personal injury lawyer in order to ...
(Date:2/28/2015)... 2015 For those people who are ... Mesothelioma Applied Research Foundation (Meso Foundation) will ... 3, starting at 9:30 AM. , The live broadcast ... broadcast can be accessed through any browser on a ... The Symposium is a unique event that covers important ...
(Date:2/28/2015)... MO (PRWEB) February 28, 2015 ... provider of outsourced sales, marketing and supply chain ... client, BIOTA Botanicals, is bringing its award winning ... worldwide, BIOTA Botanicals’ products are specifically created to ... care experts, BIOTA is committed to marrying science ...
Breaking Medicine News(10 mins):Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... linked to iron deficiency, intravenous administration of iron increases ... says a Turkish study. ,Since oral iron replacement ... first choice for treatment for iron-deficiency anemia, Dr. Ragip ... it seems that intravenous iron sucrose is a safe ...
... 'small is good' and those small portions help us keep over ... pour 20-30% more alcohol // into short , wide glasses than ... believe that tall glasses hold more. The study finds mention ... public but seasoned and professional bartenders do the same mistake or ...
... of Jharkhand has given health the status of industry. ... to receive all facilities provided under the industrial policy. ... and infrastructure support. ,The government move is ... the health sector in state, where half the population ...
... Woods with other scientists from British Cardiac Society, ... the Primary Care Cardiovascular Society // and ... preventing cardiovascular risks of heart attacks, stroke and ... drafted to reduce the risk of developing heart ...
... of Medicine in St. Louis has found that survivors of ... as depressed as some studies make them out to be ... December issue of Supportive Care in Cancer. ,This study ... Center at Washington University School of Medicine and Barnes-Jewish Hospital. ...
... in the December 21 issue of the Journal of the ... radiation reduces the ability // to repair the chromosomal damage ... developing basal cell carcinoma and squamous cell carcinoma. ... is responsible for breaking DNA strands in exposed skin cells. ...
Cached Medicine News:Health News:Intravenous Iron treats anemia of pregnancy faster 2
An automatic system for determining erythrocyte sedimentation rate (ESR) in EDTA tube and using cell counter racks....
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
The MICROsed-System is the ideal system back up support to be used as front-line instrument with small workloads....
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
Medicine Products: